                               SEQUENCE LISTING

<110> APELLIS PHARMACEUTICALS, INC.
 
<120> VIRAL VECTOR THERAPY

<130> 2008575-0446

<140> PCT/US2020/040741
<141> 2020-07-02

<150> 62/935,569
<151> 2019-11-14

<150> 62/875,925
<151> 2019-07-18

<150> 62/871,700
<151> 2019-07-08

<150> 62/871,058
<151> 2019-07-05

<160> 75   

<170> PatentIn version 3.5

<210> 1
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<221> MISC_FEATURE
<222> (2)..(12)
<223> Disulfide bond

<400> 1
Ile Cys Val Val Gln Asp Trp Gly His His Arg Cys Thr 
1               5                   10              


<210> 2
<211> 42
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      polypeptide


<220>
<221> MOD_RES
<222> (1)..(19)
<223> Any independently selected amino acid or amino
      acid analog

<220>
<221> MISC_FEATURE
<222> (1)..(19)
<223> This region may encompass 2 to 19 residues, wherein
      some residues may be absent

<220>
<221> MOD_RES
<222> (22)..(22)
<223> Trp or an analog of Trp

<220>
<221> MOD_RES
<222> (24)..(42)
<223> Any independently selected amino acid or amino
      acid analog

<220>
<221> MISC_FEATURE
<222> (24)..(42)
<223> This region may encompass 2 to 19 residues, wherein
      some residues may be absent

<220> 
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 2
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10                  15      


Xaa Xaa Xaa Gln Asp Xaa Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
            20                  25                  30          


Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
        35                  40                  


<210> 3
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<221> MOD_RES
<222> (1)..(1)
<223> Trp, an analog of Trp, or other amino acid or amino acid
      analog comprising at least one aromatic ring 

<220>
<221> MOD_RES
<222> (4)..(4)
<223> Trp, an analog of Trp, or other amino acid or amino acid
      analog comprising at least one aromatic ring 

<220> 
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 3
Xaa Gln Asp Xaa Gly 
1               5   


<210> 4
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<221> MOD_RES
<222> (1)..(1)
<223> Trp, an analog of Trp, or other amino acid or amino acid 
      analog comprising at least one aromatic side chain 

<220>
<221> MOD_RES
<222> (4)..(4)
<223> Trp, an analog of Trp, or other amino acid or amino acid 
      analog comprising at least one aromatic side chain 

<220>
<221> MOD_RES
<222> (6)..(6)
<223> His, Ala, analog of Ala, Phe, Trp or analog of Trp

<220> 
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 4
Xaa Gln Asp Xaa Gly Xaa 
1               5       


<210> 5
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<221> MOD_RES
<222> (1)..(3)
<223> Any independently selected amino acid or amino
      acid analog

<220>
<221> MOD_RES
<222> (4)..(4)
<223> Trp or analog of Trp

<220>
<221> MOD_RES
<222> (7)..(7)
<223> Trp or analog of Trp

<220>
<221> MOD_RES
<222> (9)..(13)
<223> Any independently selected amino acid or amino
      acid analog

<220> 
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 5
Xaa Xaa Xaa Xaa Gln Asp Xaa Gly Xaa Xaa Xaa Xaa Xaa 
1               5                   10              


<210> 6
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<221> MOD_RES
<222> (1)..(2)
<223> Ile, Val, Leu, B1-Ile, B1-Val, B1-Leu or a dipeptide 
      comprising Gly-Ile or B1-Gly-Ile, wherein B1 represents 
      a first blocking moiety 

<220>
<221> MISC_FEATURE
<222> (1)..(2)
<223> This region may encompass 1 to 2 residues, wherein some
      positions may be absent

<220>
<221> MISC_FEATURE
<222> (3)..(13)
<223> Disulfide bond

<220>
<221> MOD_RES
<222> (5)..(5)
<223> Independently selected from Trp or analogs of Trp

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Independently selected from Trp or analogs of Trp

<220>
<221> MOD_RES
<222> (10)..(10)
<223> His, Ala or an analog of Ala, Phe, Trp or an analog 
      of Trp 

<220>
<221> MOD_RES
<222> (14)..(16)
<223> L-Thr, D-Thr, Ile, Val, Gly, a dipeptide selected from Thr-Ala
      or Thr-Asn, or a tripeptide comprising Thr-Ala-Asn, wherein
      a c-term -OH of any of the L-Thr, D-Thr, Ile, Val, Gly,
      Ala or Asn is optionally replaced by a second blocking moiety 

<220>
<221> MISC_FEATURE
<222> (14)..(16)
<223> This region may encompass 1 to 3 residues, wherein some
      positions may be absent 

<220> 
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 6
Xaa Xaa Cys Val Xaa Gln Asp Xaa Gly Xaa His Arg Cys Xaa Xaa Xaa 
1               5                   10                  15      


<210> 7
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<221> MOD_RES
<222> (1)..(2)
<223> Ile, Val, Leu, Ac-Ile, Ac-Val, Ac-Leu or a dipeptide
      comprising Gly-Ile or Ac-Gly-Ile

<220>
<221> MISC_FEATURE
<222> (1)..(2)
<223> This region may encompass 1 to 2 residues, wherein some
      positions may be absent

<220>
<221> MISC_FEATURE
<222> (3)..(13)
<223> Disulfide bond

<220>
<221> MOD_RES
<222> (5)..(5)
<223> Independently selected from Trp or analogs of Trp 

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Independently selected from Trp or analogs of Trp 

<220>
<221> MOD_RES
<222> (10)..(10)
<223> His, Ala or an analog of Ala, Phe, Trp or an analog
      of Trp 

<220>
<221> MOD_RES
<222> (14)..(16)	
<223> L-Thr, D-Thr, Ile, Val, Gly, a dipeptide selected from Thr-Ala
      or Thr-Asn, or a tripeptide comprising Thr-Ala-Asn, wherein a
      c-term -OH of any of L-Thr, D-Thr, Ile, Val, Gly, Ala, or Asn
      is optionally replaced by -NH2

<220>
<221> MISC_FEATURE
<222> (14)..(16)
<223> This region may encompass 1 to 3 residues, wherein some
      positions may be absent 

<220> 
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 7
Xaa Xaa Cys Val Xaa Gln Asp Xaa Gly Xaa His Arg Cys Xaa Xaa Xaa 
1               5                   10                  15      


<210> 8
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term H

<220>
<223> C-term CONH2

<400> 8
Ile Cys Val Val Gln Asp Trp Gly His His Arg Cys Thr 
1               5                   10              


<210> 9
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<223> C-term CONH2

<400> 9
Ile Cys Val Val Gln Asp Trp Gly His His Arg Cys Thr 
1               5                   10              


<210> 10
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<223> C-term CONH2

<400> 10
Ile Cys Val Tyr Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 11
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<223> C-term COOH

<400> 11
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 12
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<223> C-term CONH2

<400> 12
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 13
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<221> MOD_RES
<222> (13)..(13)
<223> d-Thr

<220>
<223> C-term COOH

<400> 13
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 14
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<221> MOD_RES
<222> (4)..(4)
<223> 2-Nal

<220>
<223> C-term CONH2

<400> 14
Ile Cys Val Ala Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 15
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<221> MOD_RES
<222> (4)..(4)
<223> 2-Nal

<220>
<223> C-term COOH

<400> 15
Ile Cys Val Ala Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 16
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<221> MOD_RES
<222> (4)..(4)
<223> 1-Nal

<220>
<223> C-term COOH

<400> 16
Ile Cys Val Ala Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 17
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<221> MOD_RES
<222> (4)..(4)
<223> 2-Igl

<220>
<223> C-term CONH2

<400> 17
Ile Cys Val Gly Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 18
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<221> MOD_RES
<222> (4)..(4)
<223> 2-Igl

<220>
<223> C-term COOH

<400> 18
Ile Cys Val Gly Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 19
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<221> MOD_RES
<222> (4)..(4)
<223> Dht

<220>
<223> C-term COOH

<400> 19
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 20
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<221> MOD_RES
<222> (4)..(4)
<223> Bpa

<220>
<223> C-term COOH

<400> 20
Ile Cys Val Phe Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 21
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<221> MOD_RES
<222> (4)..(4)
<223> Bpa

<220>
<223> C-term CONH2

<400> 21
Ile Cys Val Phe Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 22
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<221> MOD_RES
<222> (4)..(4)
<223> Bta

<220>
<223> C-term COOH

<400> 22
Ile Cys Val Xaa Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 23
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<221> MOD_RES
<222> (4)..(4)
<223> Bta

<220>
<223> C-term CONH2

<400> 23
Ile Cys Val Xaa Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 24
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<221> MOD_RES
<222> (9)..(9)
<223> 2-Abu

<220>
<223> C-term CONH2

<400> 24
Ile Cys Val Trp Gln Asp Trp Gly Xaa His Arg Cys Thr 
1               5                   10              


<210> 25
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term H

<220>
<223> C-term COOH

<400> 25
Gly Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr Ala Asn 
1               5                   10                  15      


<210> 26
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<221> MOD_RES
<222> (4)..(4)
<223> 5f-Trp

<220>
<223> C-term CONH2

<400> 26
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 27
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<221> MOD_RES
<222> (4)..(4)
<223> 5-methyl-Trp

<220>
<223> C-term CONH2

<400> 27
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 28
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<221> MOD_RES
<222> (4)..(4)
<223> 1-methyl-Trp

<220>
<223> C-term CONH2

<400> 28
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 29
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<221> MOD_RES
<222> (7)..(7)
<223> 5f-Trp

<220>
<223> C-term CONH2

<400> 29
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 30
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<221> MOD_RES
<222> (4)..(4)
<223> 5f-Trp

<220>
<221> MOD_RES
<222> (7)..(7)
<223> 5f-Trp

<220>
<223> C-term CONH2

<400> 30
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 31
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<221> MOD_RES
<222> (4)..(4)
<223> 5-methyl-Trp

<220>
<221> MOD_RES
<222> (7)..(7)
<223> 5f-Trp

<220>
<223> C-term CONH2

<400> 31
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 32
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<221> MOD_RES
<222> (4)..(4)
<223> 1-methyl-Trp

<220>
<221> MOD_RES
<222> (7)..(7)
<223> 5f-Trp

<220>
<223> C-term CONH2

<400> 32
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 33
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term H

<220>
<221> MOD_RES
<222> (5)..(5)
<223> 6f-Trp

<220>
<221> MOD_RES
<222> (8)..(8)
<223> 6f-Trp

<220>
<223> C-term COOH

<400> 33
Gly Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr Asn 
1               5                   10                  15  


<210> 34
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<221> MOD_RES
<222> (4)..(4)
<223> 1-formyl-Trp

<220>
<223> C-term CONH2

<400> 34
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 35
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<221> MOD_RES
<222> (4)..(4)
<223> 1-methoxy-Trp

<220>
<223> C-term CONH2

<400> 35
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 36
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term H

<220>
<221> MOD_RES
<222> (5)..(5)
<223> 5f-Trp

<220>
<221> MOD_RES
<222> (8)..(8)
<223> 5f-Trp

<220>
<223> C-term COOH

<400> 36
Gly Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr Asn 
1               5                   10                  15  


<210> 37
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220> 
<221> MISC_FEATURE
<222> (2)..(12)
<223> Disulfide bond 

<220> 
<221> MOD_RES
<222> (4)..(4)
<223> (1Me)Trp  

<400> 37
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 38
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220> 
<223> N-term Maleimide-(CH2)5-C(=O) 

<220> 
<221> MISC_FEATURE
<222> (2)..(12)
<223> Disulfide bond 

<220> 
<221> MOD_RES
<222> (4)..(4)
<223> (1Me)Trp 

<220> 
<223> C-term NH2 

<400> 38
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 39
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220> 
<223> N-term Ac 

<220> 
<221> MISC_FEATURE
<222> (2)..(12)
<223> Disulfide bond 

<220> 
<221> MOD_RES
<222> (4)..(4)
<223> (1Me)Trp 

<220> 
<223> C-term (C=O)-(CH2)5-maleimide 

<400> 39
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 40
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220> 
<223> N-term Maleimide-(CH2)2-C(=O)-NH-CH2CH2OCH2CH2O
      CH2CH2C(=O)

<220> 
<221> MISC_FEATURE
<222> (2)..(12)
<223> Disulfide bond 

<220> 
<221> MOD_RES
<222> (4)..(4)
<223> (1Me)Trp 

<220> 
<223> C-term NH2 

<400> 40
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 41
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220> 
<223> N-term Maleimide-(CH2)2-C(=O)-NH-CH2CH2OCH2CH2C(=O) 

<220> 
<221> MISC_FEATURE
<222> (2)..(12)
<223> Disulfide bond 

<220> 
<221> MOD_RES
<222> (4)..(4)
<223> (1Me)Trp 

<220> 
<223> C-term NH2 

<400> 41
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 42
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220> 
<223> N-term Maleimide-(CH2)3-C(=O)-NH-CH2CH2OCH2CH2
      OCH2C(=O) 

<220> 
<221> MISC_FEATURE
<222> (2)..(12)
<223> Disulfide bond 

<220> 
<221> MOD_RES
<222> (4)..(4)
<223> (1Me)Trp 

<220> 
<223> C-term NH2 

<400> 42
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 43
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220> 
<223> N-term Maleimide-(CH2)5-C(=O)-NH-CH2CH2OCH2CH2
      OCH2C(=O) 

<220> 
<221> MISC_FEATURE
<222> (2)..(12)
<223> Disulfide bond 

<220> 
<221> MOD_RES
<222> (4)..(4)
<223> (1Me)Trp 

<220> 
<223> C-term NH2 

<400> 43
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 44
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220> 
<223> N-term Maleimide-(CH2)4-C(=O)-NH-CH2CH2OCH2CH2
      OCH2CH2C(=O) 

<220> 
<221> MISC_FEATURE
<222> (2)..(12)
<223> Disulfide bond 

<220> 
<221> MOD_RES
<222> (4)..(4)
<223> (1Me)Trp 

<220> 
<223> C-term NH2 

<400> 44
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 45
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220> 
<223> N-term Maleimide-(CH2)2-C(=O)-NH-CH2CH2OCH2CH2
      OCH2CH2C(=O) 

<220> 
<221> MISC_FEATURE
<222> (2)..(12)
<223> Disulfide bond 

<220> 
<221> MOD_RES
<222> (4)..(4)
<223> (1Me)Trp 

<220> 
<223> C-term NH2 

<400> 45
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 46
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220> 
<223> N-term Maleimide-(CH2)5-C(=O)-NH-CH2CH2OCH2CH2
      OCH2C(=O) 

<220> 
<221> MISC_FEATURE
<222> (2)..(12)
<223> Disulfide bond 

<220> 
<221> MOD_RES
<222> (4)..(4)
<223> (1Me)Trp 

<220> 
<223> C-term NH2 

<400> 46
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 47
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220> 
<223> N-term Ac 

<220> 
<221> MISC_FEATURE
<222> (2)..(12)
<223> Disulfide bond 

<220> 
<221> MOD_RES
<222> (4)..(4)
<223> (1Me)Trp 

<220> 
<223> C-term NH2 

<400> 47
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr Lys 
1               5                   10                  


<210> 48
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220> 
<223> N-term Ac 

<220> 
<221> MISC_FEATURE
<222> (2)..(12)
<223> Disulfide bond 

<220> 
<221> MOD_RES
<222> (4)..(4)
<223> (1Me)Trp 

<220> 
<223> C-term NH2 

<400> 48
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr Gly Gly Gly 
1               5                   10                  15      


Gly Gly Lys 
        


<210> 49
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220> 
<223> N-term NH2(CH2)5C(=O) 

<220> 
<221> MOD_RES
<222> (4)..(4)
<223> (1Me)Trp 

<220> 
<223> C-term NH2 

<400> 49
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 50
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220> 
<223> N-term NH2(CH2CH2O)2CH2C(=O) 

<220> 
<221> MOD_RES
<222> (4)..(4)
<223> (1Me)Trp 

<220> 
<223> C-term NH2 

<400> 50
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 51
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220> 
<223> N-term Ac 

<220> 
<221> MISC_FEATURE
<222> (2)..(12)
<223> Disulfide bond 

<220> 
<221> MOD_RES
<222> (4)..(4)
<223> (1Me)Trp 

<220> 
<221> MOD_RES
<222> (14)..(14)
<223> NH-CH2CH2OCH2CH2OCH2-C(=O)-Lys 

<220> 
<223> C-term NH2 

<400> 51
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr Lys 
1               5                   10                  


<210> 52
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220> 
<223> N-term Ac 

<220> 
<221> MISC_FEATURE
<222> (2)..(12)
<223> Disulfide bond 

<220> 
<221> MOD_RES
<222> (4)..(4)
<223> (1Me)Trp 

<220> 
<221> MOD_RES
<222> (14)..(14)
<223> Lys-(C(=O)-(CH2)5-Mal) 

<220> 
<223> C-term NH2 

<400> 52
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr Lys 
1               5                   10                  


<210> 53
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220> 
<223> N-term Ac 

<220> 
<221> MISC_FEATURE
<222> (2)..(12)
<223> Disulfide bond 

<220> 
<221> MOD_RES
<222> (4)..(4)
<223> (1Me)Trp 

<220> 
<221> MOD_RES
<222> (19)..(19)
<223> Lys-(C(=O)-(CH2)5-Mal) 

<220> 
<223> C-term NH2 

<400> 53
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr Gly Gly Gly 
1               5                   10                  15      


Gly Gly Lys 
            


<210> 54
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220> 
<223> N-term Mal-(CH2)5-(C(=O)-NH(CH2)5C(=O) 

<220> 
<221> MOD_RES
<222> (4)..(4)
<223> (1Me)Trp 

<220> 
<223> C-term NH2 

<400> 54
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 55
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220> 
<223> N-term Mal-(CH2)5-(C(=O)NH(CH2CH2O)2CH2C(=O) 

<220> 
<221> MOD_RES
<222> (4)..(4)
<223> (1Me)Trp 

<220> 
<223> C-term NH2 

<400> 55
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 56
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220> 
<223> N-term Ac 

<220> 
<221> MISC_FEATURE
<222> (2)..(12)
<223> Disulfide bond 

<220> 
<221> MOD_RES
<222> (4)..(4)
<223> (1Me)Trp 

<220> 
<221> MOD_RES
<222> (14)..(14)
<223> NH-CH2CH2OCH2CH2OCH2-C(=O)-Lys-(C(=O)-(CH2)5-Mal) 

<220> 
<223> C-term NH2 

<400> 56
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr Lys 
1               5                   10                  


<210> 57
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220> 
<223> N-term Ac 

<220> 
<221> MISC_FEATURE
<222> (2)..(12)
<223> Disulfide bond 

<220> 
<221> MOD_RES
<222> (4)..(4)
<223> (1Me)Trp 

<220> 
<221> MOD_RES
<222> (14)..(14)
<223> Lys-C(=O)-CH2(OCH2CH2)2NH(C(=O)-(CH2)5-Mal) 

<220> 
<223> C-term NH2 

<400> 57
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr Lys 
1               5                   10                  


<210> 58
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term (CH2CH2O)nC(=O)

<220>
<221> MOD_RES
<222> (4)..(4)
<223> (1Me)Trp

<220>
<223> C-term NH2

<220> 
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 58
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10              


<210> 59
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<221> MISC_FEATURE
<222> (2)..(12)
<223> Disulfide bond

<220>
<221> MOD_RES
<222> (4)..(4)
<223> (1Me)Trp

<220>
<221> MOD_RES
<222> (14)..(14)
<223> NH-CH2CH2OCH2CH2OCH2-C(=O)-Lys-C(=O)-(CH2CH2O)n

<220>
<223> C-term NH2

<220> 
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 59
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr Lys 
1               5                   10                  


<210> 60
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<221> MISC_FEATURE
<222> (2)..(12)
<223> Disulfide bond

<220>
<221> MOD_RES
<222> (4)..(4)
<223> (1Me)Trp

<220>
<221> MOD_RES
<222> (14)..(14)
<223> Lys-C(=O)-(CH2CH2O)n

<220>
<223> C-term NH2

<220> 
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 60
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr Lys 
1               5                   10                  


<210> 61
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<221> MISC_FEATURE
<222> (2)..(12)
<223> Disulfide bond

<220>
<221> MOD_RES
<222> (4)..(4)
<223> (1Me)Trp

<220>
<221> MOD_RES
<222> (19)..(19)
<223> Lys-C(=O)-(CH2CH2O)n

<220>
<223> C-term NH2

<220> 
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 61
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr Gly Gly Gly 
1               5                   10                  15      


Gly Gly Lys 
            


<210> 62
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<221> MOD_RES
<222> (1)..(1)
<223> (CH2CH2O)nC(=O)Lys

<220>
<221> MISC_FEATURE
<222> (8)..(18)
<223> Disulfide bond

<220>
<221> MOD_RES
<222> (10)..(10)
<223> (1Me)Trp

<220>
<223> C-term NH2

<220> 
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 62
Lys Gly Gly Gly Gly Gly Ile Cys Val Trp Gln Asp Trp Gly Ala His 
1               5                   10                  15      


Arg Cys Thr 
            


<210> 63
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<221> MOD_RES
<222> (1)..(1)
<223> (CH2CH2O)nC(=O)Lys

<220>
<221> MISC_FEATURE
<222> (3)..(13)
<223> Disulfide bond

<220>
<221> MOD_RES
<222> (5)..(5)
<223> (1Me)Trp

<220>
<223> C-term NH2

<220> 
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 63
Lys Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr 
1               5                   10                  


<210> 64
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<221> MISC_FEATURE
<222> (2)..(12)
<223> Disulfide bond

<220>
<221> MOD_RES
<222> (4)..(4)
<223> (1Me)Trp

<220>
<221> MOD_RES
<222> (14)..(14)
<223> NH-CH2CH2OCH2CH2OCH2-C(=O)-Lys-(C(=O)-(CH2CH2O)n-R)

<220>
<223> C-term NH2

<220> 
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 64
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr Lys 
1               5                   10                  


<210> 65
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<221> MISC_FEATURE
<222> (2)..(12)
<223> Disulfide bond

<220>
<221> MOD_RES
<222> (4)..(4)
<223> (1Me)Trp

<220>
<221> MOD_RES
<222> (14)..(14)
<223> NH-CH2CH2OCH2CH2OCH2-C(=O)-Lys-(C(=O)-(CH2)m-
      (CH2CH2O)n-R)

<220>
<223> C-term NH2

<220> 
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 65
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr Lys 
1               5                   10                  


<210> 66
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220>
<221> MISC_FEATURE
<222> (2)..(12)
<223> Disulfide bond

<220>
<221> MOD_RES
<222> (4)..(4)
<223> (1Me)Trp

<220>
<221> MOD_RES
<222> (14)..(14)
<223> NH-CH2CH2OCH2CH2OCH2-C(=O)-Lys-(C(=O)-(CH2)m-C(=O)-
     (CH2CH2O)n-R)

<220>
<223> C-term NH2

<220> 
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 66
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr Lys 
1               5                   10                  


<210> 67
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220> 
<223> N-term Ac 

<220> 
<221> MISC_FEATURE
<222> (2)..(12)
<223> Disulfide bond 

<220> 
<221> MOD_RES
<222> (4)..(4)
<223> (1Me)Trp 

<220> 
<221> MOD_RES
<222> (14)..(14)
<223> NH-CH2CH2OCH2CH2OCH2-C(=O)-Lys-(C(=O)-(CH2)m-C(=O)
      -(CH2)j(CH2CH2O)n-R) 

<220> 
<223> C-term NH2 

<400> 67
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr Lys 
1               5                   10                  


<210> 68
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<223> N-term Ac

<220> 
<221> MISC_FEATURE
<222> (2)..(12)
<223> Disulfide bond 

<220>
<221> MOD_RES
<222> (4)..(4) 
<223> (1Me)Trp  

<220>
<221> MISC_FEATURE
<222> (13)..(14) 
<223> Residues at these positions are linked by an AEEAc moiety

<220>
<221> MOD_RES
<222> (14)..(14) 
<223> Lys-(C(=O)-(CH2)5-Mal)

<220>
<223> C-term NH2

<400> 68
Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr Lys 
1               5                   10                  


<210> 69
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<221> MOD_RES
<222> (1)..(1)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (2)..(4)
<223> Any independently selected amino acid or amino
      acid analog

<220>
<221> MOD_RES
<222> (5)..(5)
<223> Trp or analog of Trp

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Trp or analog of Trp

<220>
<221> MOD_RES
<222> (10)..(14)
<223> Any independently selected amino acid or amino
      acid analog

<220>
<221> MOD_RES
<222> (15)..(15)
<223> Any amino acid

<220> 
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 69
Xaa Xaa Xaa Xaa Xaa Gln Asp Xaa Gly Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10                  15  


<210> 70
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<221> MOD_RES
<222> (1)..(1)
<223> Any amino acid

<220>
<221> MOD_RES
<222> (2)..(3)
<223> Ile, Val, Leu, B1-Ile, B1-Val, B1-Leu or a dipeptide 
      comprising Gly-Ile or B1-Gly-Ile, wherein B1 represents 
      a first blocking moiety 

<220>
<221> MISC_FEATURE
<222> (2)..(3)
<223> This region may encompass 1 to 2 residues, wherein some
      positions may be absent

<220>
<221> MISC_FEATURE
<222> (4)..(14)
<223> Disulfide bond

<220>
<221> MOD_RES
<222> (6)..(6)
<223> Independently selected from Trp or analogs of Trp

<220>
<221> MOD_RES
<222> (9)..(9)
<223> Independently selected from Trp or analogs of Trp

<220>
<221> MOD_RES
<222> (11)..(11)
<223> His, Ala or an analog of Ala, Phe, Trp or an analog 
      of Trp 

<220>
<221> MOD_RES
<222> (15)..(17)
<223> L-Thr, D-Thr, Ile, Val, Gly, a dipeptide selected from Thr-Ala
      or Thr-Asn, or a tripeptide comprising Thr-Ala-Asn, wherein
      a C-term -OH of any of the L-Thr, D-Thr, Ile, Val, Gly,
      Ala or Asn is optionally replaced by a second blocking moiety 

<220>
<221> MISC_FEATURE
<222> (15)..(17)
<223> This region may encompass 1 to 3 residues, wherein some
      positions may be absent 

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Any amino acid

<220> 
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 70
Xaa Xaa Xaa Cys Val Xaa Gln Asp Xaa Gly Xaa His Arg Cys Xaa Xaa 
1               5                   10                  15      


Xaa Xaa 
        


<210> 71
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<221> MOD_RES
<222> (1)..(1) 
<223> Any amino acid

<220>
<221> MOD_RES
<222> (2)..(2) 
<223> Ile or Gly

<220>
<221> MOD_RES
<222> (3)..(3) 
<223> Ile or Cys

<220>
<221> MOD_RES
<222> (4)..(4) 
<223> Val or Cys
     
<220>
<221> MOD_RES
<222> (5)..(5) 
<223> Val, Tyr, Trp, 2-Nal, 1-Nal, 2-Igl, Dht, Bpa, Bta,  
      5f-Trp, 5-methyl-Trp, 1-methyl-Trp, 1-formyl-Trp or 
      1-methyoxy-Trp

<220>
<221> MOD_RES
<222> (6)..(6) 
<223> Gln, Trp, 6f-Trp or 5f-Trp

<220>
<221> MOD_RES
<222> (7)..(7) 
<223> Asp or Gln

<220>
<221> MOD_RES
<222> (8)..(8) 
<223> Trp, Asp or 5f-Trp

<220>
<221> MOD_RES
<222> (9)..(9) 
<223> Gly, Trp, 6f-Trp or 5f-Trp

<220>
<221> MOD_RES
<222> (10)..(10) 
<223> His, Ala, 2-Abu or Gly

<220>
<221> MOD_RES
<222> (11)..(11) 
<223> His or Ala

<220>
<221> MOD_RES
<222> (12)..(12) 
<223> Arg or His

<220>
<221> MOD_RES
<222> (13)..(13) 
<223> Cys or Arg

<220>
<221> MOD_RES
<222> (14)..(14) 
<223> Thr, D-Thr or Cys

<220>
<221> MOD_RES
<222> (15)..(15) 
<223> Any amino acid

<220> 
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 71
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10                  15  


<210> 72
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<221> MOD_RES
<222> (1)..(1)
<223> Any amino acid

<220>
<221> MISC_FEATURE
<222> (3)..(13)
<223> Disulfide bond

<220>
<221> MOD_RES
<222> (5)..(5)
<223> Trp(Me)

<220>
<221> MOD_RES
<222> (9)..(9)
<223> mGly

<220>
<221> MOD_RES
<222> (14)..(14)
<223> mIle

<220>
<221> MOD_RES
<222> (15)..(15)
<223> Any amino acid

<220> 
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 72
Xaa Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Ile Xaa 
1               5                   10                  15  


<210> 73
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 73
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn 
1               5                   10  


<210> 74
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 74
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 
1               5                   10                  15      


Thr 
    


<210> 75
<211> 5148
<212> RNA
<213> Homo sapiens

<400> 75
agauaaaaag ccagcuccag caggcgcugc ucacuccucc ccauccucuc ccucuguccc       60

ucugucccuc ugacccugca cugucccagc accaugggac ccaccucagg ucccagccug      120

cugcuccugc uacuaaccca ccucccccug gcucugggga gucccaugua cucuaucauc      180

acccccaaca ucuugcggcu ggagagcgag gagaccaugg ugcuggaggc ccacgacgcg      240

caaggggaug uuccagucac uguuacuguc cacgacuucc caggcaaaaa acuagugcug      300

uccagugaga agacugugcu gaccccugcc accaaccaca ugggcaacgu caccuucacg      360

aucccagcca acagggaguu caagucagaa aaggggcgca acaaguucgu gaccgugcag      420

gccaccuucg ggacccaagu gguggagaag guggugcugg ucagccugca gagcggguac      480

cucuucaucc agacagacaa gaccaucuac accccuggcu ccacaguucu cuaucggauc      540

uucaccguca accacaagcu gcuacccgug ggccggacgg ucauggucaa cauugagaac      600

ccggaaggca ucccggucaa gcaggacucc uugucuucuc agaaccagcu uggcgucuug      660

cccuugucuu gggacauucc ggaacucguc aacaugggcc aguggaagau ccgagccuac      720

uaugaaaacu caccacagca ggucuucucc acugaguuug aggugaagga guacgugcug      780

cccaguuucg aggucauagu ggagccuaca gagaaauucu acuacaucua uaacgagaag      840

ggccuggagg ucaccaucac cgccagguuc cucuacggga agaaagugga gggaacugcc      900

uuugucaucu ucgggaucca ggauggcgaa cagaggauuu cccugccuga aucccucaag      960

cgcauuccga uugaggaugg cucgggggag guugugcuga gccggaaggu acugcuggac     1020

ggggugcaga acccccgagc agaagaccug guggggaagu cuuuguacgu gucugccacc     1080

gucaucuugc acucaggcag ugacauggug caggcagagc gcagcgggau ccccaucgug     1140

accucucccu accagaucca cuucaccaag acacccaagu acuucaaacc aggaaugccc     1200

uuugaccuca ugguguucgu gacgaacccu gauggcucuc cagccuaccg aguccccgug     1260

gcaguccagg gcgaggacac ugugcagucu cuaacccagg gagauggcgu ggccaaacuc     1320

agcaucaaca cacaccccag ccagaagccc uugagcauca cggugcgcac gaagaagcag     1380

gagcucucgg aggcagagca ggcuaccagg accaugcagg cucugcccua cagcaccgug     1440

ggcaacucca acaauuaccu gcaucucuca gugcuacgua cagagcucag acccggggag     1500

acccucaacg ucaacuuccu ccugcgaaug gaccgcgccc acgaggccaa gauccgcuac     1560

uacaccuacc ugaucaugaa caagggcagg cuguugaagg cgggacgcca ggugcgagag     1620

cccggccagg accugguggu gcugccccug uccaucacca ccgacuucau cccuuccuuc     1680

cgccuggugg cguacuacac gcugaucggu gccagcggcc agagggaggu gguggccgac     1740

uccguguggg uggacgucaa ggacuccugc gugggcucgc uggugguaaa aagcggccag     1800

ucagaagacc ggcagccugu accugggcag cagaugaccc ugaagauaga gggugaccac     1860

ggggcccggg ugguacuggu ggccguggac aagggcgugu ucgugcugaa uaagaagaac     1920

aaacugacgc agaguaagau cugggacgug guggagaagg cagacaucgg cugcaccccg     1980

ggcaguggga aggauuacgc cggugucuuc uccgacgcag ggcugaccuu cacgagcagc     2040

aguggccagc agaccgccca gagggcagaa cuucagugcc cgcagccagc cgcccgccga     2100

cgccguuccg ugcagcucac ggagaagcga auggacaaag ucggcaagua ccccaaggag     2160

cugcgcaagu gcugcgagga cggcaugcgg gagaacccca ugagguucuc gugccagcgc     2220

cggacccguu ucaucucccu gggcgaggcg ugcaagaagg ucuuccugga cugcugcaac     2280

uacaucacag agcugcggcg gcagcacgcg cgggccagcc accugggccu ggccaggagu     2340

aaccuggaug aggacaucau ugcagaagag aacaucguuu cccgaaguga guucccagag     2400

agcuggcugu ggaacguuga ggacuugaaa gagccaccga aaaauggaau cucuacgaag     2460

cucaugaaua uauuuuugaa agacuccauc accacguggg agauucuggc ugugagcaug     2520

ucggacaaga aagggaucug uguggcagac cccuucgagg ucacaguaau gcaggacuuc     2580

uucaucgacc ugcggcuacc cuacucuguu guucgaaacg agcaggugga aauccgagcc     2640

guucucuaca auuaccggca gaaccaagag cucaagguga ggguggaacu acuccacaau     2700

ccagccuucu gcagccuggc caccaccaag aggcgucacc agcagaccgu aaccaucccc     2760

cccaaguccu cguuguccgu uccauauguc aucgugccgc uaaagaccgg ccugcaggaa     2820

guggaaguca aggcugcugu cuaccaucau uucaucagug acggugucag gaagucccug     2880

aaggucgugc cggaaggaau cagaaugaac aaaacugugg cuguucgcac ccuggaucca     2940

gaacgccugg gccgugaagg agugcagaaa gaggacaucc caccugcaga ccucagugac     3000

caagucccgg acaccgaguc ugagaccaga auucuccugc aagggacccc aguggcccag     3060

augacagagg augccgucga cgcggaacgg cugaagcacc ucauugugac ccccucgggc     3120

ugcggggaac agaacaugau cggcaugacg cccacgguca ucgcugugca uuaccuggau     3180

gaaacggagc agugggagaa guucggccua gagaagcggc agggggccuu ggagcucauc     3240

aagaaggggu acacccagca gcuggccuuc agacaaccca gcucugccuu ugcggccuuc     3300

gugaaacggg cacccagcac cuggcugacc gccuacgugg ucaaggucuu cucucuggcu     3360

gucaaccuca ucgccaucga cucccaaguc cucugcgggg cuguuaaaug gcugauccug     3420

gagaagcaga agcccgacgg ggucuuccag gaggaugcgc ccgugauaca ccaagaaaug     3480

auugguggau uacggaacaa caacgagaaa gacauggccc ucacggccuu uguucucauc     3540

ucgcugcagg aggcuaaaga uauuugcgag gagcagguca acagccugcc aggcagcauc     3600

acuaaagcag gagacuuccu ugaagccaac uacaugaacc uacagagauc cuacacugug     3660

gccauugcug gcuaugcucu ggcccagaug ggcaggcuga aggggccucu ucuuaacaaa     3720

uuucugacca cagccaaaga uaagaaccgc ugggaggacc cugguaagca gcucuacaac     3780

guggaggcca cauccuaugc ccucuuggcc cuacugcagc uaaaagacuu ugacuuugug     3840

ccucccgucg ugcguuggcu caaugaacag agauacuacg gugguggcua uggcucuacc     3900

caggccaccu ucaugguguu ccaagccuug gcucaauacc aaaaggacgc cccugaccac     3960

caggaacuga accuugaugu gucccuccaa cugcccagcc gcagcuccaa gaucacccac     4020

cguauccacu gggaaucugc cagccuccug cgaucagaag agaccaagga aaaugagggu     4080

uucacaguca cagcugaagg aaaaggccaa ggcaccuugu cgguggugac aauguaccau     4140

gcuaaggcca aagaucaacu caccuguaau aaauucgacc ucaaggucac cauaaaacca     4200

gcaccggaaa cagaaaagag gccucaggau gccaagaaca cuaugauccu ugagaucugu     4260

accagguacc ggggagacca ggaugccacu augucuauau uggacauauc caugaugacu     4320

ggcuuugcuc cagacacaga ugaccugaag cagcuggcca augguguuga cagauacauc     4380

uccaaguaug agcuggacaa agccuucucc gauaggaaca cccucaucau cuaccuggac     4440

aaggucucac acucugagga ugacugucua gcuuucaaag uucaccaaua cuuuaaugua     4500

gagcuuaucc agccuggagc agucaagguc uacgccuauu acaaccugga ggaaagcugu     4560

acccgguucu accauccgga aaaggaggau ggaaagcuga acaagcucug ccgugaugaa     4620

cugugccgcu gugcugagga gaauugcuuc auacaaaagu cggaugacaa ggucacccug     4680

gaagaacggc uggacaaggc cugugagcca ggaguggacu auguguacaa gacccgacug     4740

gucaagguuc agcuguccaa ugacuuugac gaguacauca uggccauuga gcagaccauc     4800

aagucaggcu cggaugaggu gcagguugga cagcagcgca cguucaucag ccccaucaag     4860

ugcagagaag cccugaagcu ggaggagaag aaacacuacc ucaugugggg ucucuccucc     4920

gauuucuggg gagagaagcc caaccucagc uacaucaucg ggaaggacac uuggguggag     4980

cacuggcccg aggaggacga augccaagac gaagagaacc agaaacaaug ccaggaccuc     5040

ggcgccuuca ccgagagcau gguugucuuu gggugcccca acugaccaca cccccauucc     5100

cccacuccag auaaagcuuc aguuauaucu caaaaaaaaa aaaaaaaa                  5148


